Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 502,100 shares, an increase of 8.2% from the November 30th total of 463,900 shares. Approximately 3.5% of the shares of the stock are sold short. Based on an average daily volume of 124,000 shares, the days-to-cover ratio is currently 4.0 days.

Institutional Investors Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Geode Capital Management LLC boosted its holdings in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 12.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 146,500 shares of the company’s stock after acquiring an additional 16,485 shares during the quarter. Geode Capital Management LLC owned 0.90% of Acurx Pharmaceuticals worth $278,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.53% of the company’s stock.

Acurx Pharmaceuticals Price Performance

Shares of NASDAQ ACXP opened at $0.81 on Thursday. Acurx Pharmaceuticals has a 1-year low of $0.72 and a 1-year high of $5.28. The business’s 50 day moving average is $1.31 and its two-hundred day moving average is $1.84. The stock has a market capitalization of $13.75 million, a P/E ratio of -0.75 and a beta of -1.86.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. During the same quarter in the previous year, the firm earned ($0.24) EPS. As a group, equities research analysts anticipate that Acurx Pharmaceuticals will post -0.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a research note on Tuesday, December 10th.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.